A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

To reduce care disparities and prevent them from exacerbating among people living with HIV who have long COVID, education and ...

Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...